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Sphingolipids: the nexus between Gaucher




Sphingolipids constitute a diverse array of lipids in which fatty acids are linked through amide bonds to a long-
chain base, and, structurally, they form the building blocks of eukaryotic membranes. Ceramide is the simplest and
serves as a precursor for the synthesis of the three main types of complex sphingolipids; sphingomyelins, glyco-
sphingolipids and gangliosides. Sphingolipids are no longer considered mere structural spectators, but bioactive
molecules with functions beyond providing a mechanically stable and chemically resistant barrier to a diverse array
of cellular processes. Although sphingolipids form a somewhat minor component of the total cellular lipid pool,
their accumulation in certain cells forms the basis of many diseases. Human diseases caused by alterations in the
metabolism of sphingolipids are conventionally inborn errors of degradation, the most common being Gaucher
disease, in which the catabolism of glucosylceramide is defective and accumulates. Insulin resistance has been
reported in patients with Gaucher disease and this article presents evidence that this is due to perturbations in the
metabolism of sphingolipids. Ceramide and the more complex sphingolipids, the gangliosides, are constituents of
specialised membrane microdomains termed lipid rafts. Lipid rafts play a role in facilitating and regulating lipid and
protein interactions in cells, and their unique lipid composition enables them to carry out this role. The lipid
composition of rafts is altered in cell models of Gaucher disease which may be responsible for impaired lipid and
protein sorting observed in this disorder, and consequently pathology. Lipid rafts are also necessary for correct
insulin signalling, and a perturbed lipid raft composition may impair insulin signalling. Unravelling common nodes
of interaction between insulin resistance and Gaucher disease may lead to a better understanding of the biochem-
ical mechanisms behind pathology.
Introduction
Sphingolipids have become the subject of a number of bio-
chemical processes and as such have earned the topical
label of “bioactivity” [1]. Sphingolipids are also implemen-
ted in a number of disease states not only when their
metabolism is affected, but when seemingly unrelated cel-
lular homeostatic mechanisms are imbalanced. Sphingoli-
pids are amphipathic molecules with varying degrees of
hydrophobic and hydrophilic properties. The hydrophobic
region comprises a long-chain base, sometimes referred to
as a sphingoid base, which is linked through an amide
bond to a fatty acid (Figure 1). The sphingoid base is
usually 18 carbons in length, with the C20 being somewhat
less common (reviewed in [2]). The hydrophilic region in
the simplest sphingolipids can consist of just hydroxyl
groups, whereas the more complex sphingolipids have
phosphates and sugar residues attached. Given there are at
least five different sphingoid bases present in mammalian
cells with more than 20 arrangements of fatty acids differ-
ing in length of the alkyl chain and level of both saturation
and hydroxylation, coupled with more than 500 carbohy-
drate structures reported in the glycosphingolipids, the
number of possible structures is considerable [1,3].
Although a paradigm of combinatorial biosynthesis has
been described to address the high degree of complexity
[4], how cells deal with such lipid complexity is a central
biochemical question. This can be taken to an extra
dimension when considering the aberrations that can
occur in a cell’s management of lipids and how this is
linked to disease.
Human diseases caused by alterations in the metabolism
of sphingolipids are generally disorders of their degrada-
tion [5]. Traditionally the hallmark is the sphingolipidoses,
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any medium, provided the original work is properly cited.named after the lipids that accumulate. They are a group
of relatively rare inborn errors of metabolism caused by
gene defects encoding proteins in the lysosomal degrada-
tion of sphingolipids [6]. Consequently the sphingolipid
substrate for the defective protein accumulates in affected
cells. Considered the prototype, Gaucher disease results
from a deficiency of acid b-glucosidase, the enzyme
responsible for the lysosomal hydrolysis of the sphingoli-
pid, glucosylceramide, to glucose and ceramide [7]. Aside
from the accumulation of glucosylceramide, a number of
other secondarily stored sphingolipids reside in Gaucher
disease [8,9]. A growing body of evidence now supports a
role for aberrant accumulation of sphingolipids in condi-
tions of insulin resistance [10], and this review explores
the connection between sphingolipid alterations in Gau-
cher disease and how this is similar in insulin resistance.
Structure of Sphingolipids
The simplest of all the sphingolipids is ceramide, which
consists of a long-chain (sphingoid) base, commonly 18
carbons in length, linked to a fatty acid via an amide
bond. The fatty acids in ceramide vary between 2 and 28
carbon atoms in the acyl chain and saturation. Ceramide
provides the platform for both the synthesis and catabo-
lism of the complex sphingolipids and is therefore often
referred to as the ‘hub’ of sphingolipid metabolism [11].
There are three main types of sphingolipids which differ
in their hydrophilic attachments onto ceramide. The first
of these are the sphingomyelins which have a phosphory-
choline or phosphoroethanolamine molecule with an
ether linkage to the 1-hydroxy group of a ceramide; the
glycosphingolipids which are ceramides with one or
more sugar residues joined through a b-glycosidic link-
age; and lastly the gangliosides which have at least three
sugars, one of which must be sialic acid (Figure 1).
Sphingolipid Metabolism
Sphingolipid metabolism is a complex interconnected
network that is regulated by the synthesis and
degradation of the sphingolipids themselves. Alterations
in the production of individual sphingolipids effects the
levels of sphingolipids that serve as substrates as well as
the sphingolipid products that ensue [12]. For example,
an enzyme that requires ceramide as a substrate to
synthesise sphingomyelin, potentially also functions to
regulate ceramide levels, as well as the many metabolites
of ceramide, including sphingomyelin.
Synthesis
De novo synthesis of ceramide begins with the formation
of dihydrosphingosine via the linkage of serine with pal-
mitic acid derived from palmitoyl-CoA. This condensa-
tion reaction is catalysed by serine palmitoyltransferase
and takes place at the cytosolic leaflet of the ER [13].
T h er a t eo fde novo ceramide synthesis is regulated by
the availability of the precursors, palmitoyl-CoA and
serine [14]. Extracellular cytokines increase ceramide
synthesis by up-regulating the expression of serine pal-
mitoyltransferase [15]. Dihydrosphingosine can then
undergo N-acylation with various fatty acids ranging in
length from 14 to 28 carbons, with differing degrees of
saturation to produce dihydroceramide, the reaction cat-
alysed by dihydroceramide synthase. Dihydroceramide
desaturase can subsequently reduce dihydroceramide to
ceramide [16,17].
Once formed, ceramide becomes the precursor for the
synthesis of further sphingolipid types (Figure 2). Firstly,
it may undergo a simple cleavage reaction catalysed by
ceramidase to produce sphingosine, which in turn serves
as a substrate for sphingosine kinase to result in the for-
mation of sphingosine 1-phosphate, a highly bioactive
lipid [18]. Another recently identified bioactive lipid
can be formed by phosphorylation of ceramide at the
1-position by ceramide kinase to generate ceramide
1-phosphate [19].
Aside from the formation of sphingosine, sphingosine
1-phosphate and ceramide 1-phosphate, ceramide leads
to the synthesis of sphingomyelin and the glycosphingo-
lipids, including the gangliosides. Sphingomyelin is pro-
duced by the transfer of phosphorycholine from the
phospholipid, phosphatidylcholine, to the 1-hydroxyl
group of ceramide [20]. The first step in glycosphingoli-
pid synthesis is the glucosylation of ceramide forming
glucosylceramide (Figure 2) by the action of glucosylcer-
amide synthase, which transfers glucose from UDP-glu-
cose to ceramide [21]. Glucosylceramide is then
converted to lactosylceramide by b- (1,4) transfer of
galactose from UDP-galactose by galactosyltransferase I
[22]. Lactosylceramide can then serve as the substrate
for the synthesis of more complex sphingolipids, known
as the gangliosides (Figure 3). The only known excep-
tion is GM4, a major component of myelin where three
highly specific sialyltransferases (I, II and III) are
Figure 1 General chemical structure of sphingolipids.T h el o n g
chain sphingosine base, generally of 18 carbons, is linked through
an amide bond to a fatty acid. R = H is ceramide, the simplest
sphingolipid; R = phosphocholine is sphingomyelin and R = sugars
produces the glycosphingolipids including gangliosides.
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Page 2 of 12Figure 2 The fate of ceramide. Phosphorylation of ceramide by ceramide kinase generates ceramide 1-phosphate. Ceramide can be cleaved by
ceramidase to produce sphingosine from which sphingosine kinase may act upon forming sphingosine 1-phosphate. Sphingomyelin is produced
by the addition of phosphorycholine to the 1-hydroxyl on ceramide. Ceramide also undergoes glucosylation, producing glucosylceramide,
en route to the synthesis of the glycosphingolipids including the gangliosides.
Figure 3 Schematic of ganglioside synthesis. Structures and synthetic pathways for the gangliosides. Synthesis is depicted starting with
lactosylceramide (LacCer). GalNAc-T, GA2/GM2/GD2/GT2 synthase; GalT-II, GA1/GM1/GD1b/GT1c synthase; ST-IV, GM1b/GD1a/GT1b/GQ1c
synthase; ST-V, GD1c/GT1a/GQ1b/GT3 synthase; ST-VII, GD1a/GT1aa/GQ1ba/GP1ca synthase.
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mide to the mono-, di- and trisialo-gangliosides (GM3,
GD3 and GT3, respectively) [23]. Together with lactosyl-
ceramide, these three gangliosides are precursors for the
synthesis of the o-, a-, b-a n dc-series with none, one,
two or three sialic residues attached to the 3-position of
the galactose residue (Figure3 ) .T h eg a n g l i o s i d e so f
both the o-a n dc-series are only present in trace
amounts in human tissue [24].
Catabolism
Lysosomes in eukaryotic cells are the primary place for
the constitutive degradation of the complex sphingoli-
pids [25]. The stepwise breakdown of complex sphingo-
lipids terminates with ceramide which then leaves the
lysosome. Throughout different subcellular localisations,
ceramide is subsequently degraded to sphingosine and a
fatty acid by the action of a family of ceramidases [11].
For lysosomal degradation, complex sphingolipids
must reach the endosomal/lysosomal network. A num-
ber of cellular processes assist this including endocyto-
sis, phagocytosis, autophagy and direct transport, with
the choice dependent on the source of sphingolipid [26].
Once in the lysosome, monosaccharides are sequentially
cleaved by water soluble exohydrolases acting at the
non-reducing end sugar in the glycosphingolipid. Glyco-
sphingolipids are embedded in the intralysosomal mem-
brane making the presence of sphingolipid activator
proteins (SAPs) required for their degradation. SAPs
function to either mediate the interaction between the
membrane bound glycosphingolipid substrate and the
water soluble exohydrolase or activate the enzyme
directly [27]. The SAPs are five small non-enzymatic
glycoproteins that are encoded by two genes. One gene
encodes for the precursor of the GM2 activator protein
and the second gene codes for prosaposin, subsequently
proteolytically processed to the four SAPs A-D [28,29].
Ganglioside degradation begins with the action of the
lysosomal sialidase on the multi-sialogangliosides to pro-
duce the corresponding mono-sialogangliosides, GM1 and
GM2.G M1 is hydrolysed to GM2 by the removal of galactose
by a b-galactosidase in the presence of SAP-B. b-N-acetyl-
hexosaminidase removes N-acetyl-galactosamine from GM2
to produce GM3. With the aid of SAP-B, a sialidase then
breaks down GM3 into lactosylceramide and sialic acid
[30]. Subsequently, by either galactosylceramide-b-galacto-
sidase or GM1-b-galactosidase a galactose is removed to
produce glucosylceramide, which is then reduced to cera-
mide and glucose with b-glucosidase. Ceramide is also the
product of sphingomyelin hydrolysis via the action of acid
sphingomyelinase. Activator proteins SAP-B or -C are
again required for these reactions [31,32]. Further, a phos-
phorycholine moiety, also a product of sphingomyelin
hydrolysis, leaves the lysosome and is re-utilised.
Lysosomal degradation of ceramide by acid ceramidase in
the presence of SAP-D [33] is the final step and produces
sphingosine and a fatty acid, which, along with other clea-
vage products leave the lysosome. In the cytosol, sphingo-
sine can be phosphorylated to sphingosine 1-phosphate or
can be re-acetylated back to ceramide. The non-glycosy-
lated sphingolipids, ceramide and sphingomyelin, can also
be degraded outside the lysosome in other sub-cellular
locations without the need for SAPs [34]. For example, at
the plasma membrane and in the Golgi, sphingomyelin can
be degraded by two different sphingomyelinases to cera-
mide, which is subsequently cleaved by ceramidases to
sphingosine which is able to be converted by sphingosine
kinase to sphingosine 1-phosphate. The biological func-
tions of ceramide and sphingomyelin, as well as their
signaling metabolites, are believed to be dictated by their
sub-cellular location, and that enzymes of sphingolipid
metabolism regulate their cellular levels [35,36].
Functions of Sphingolipids
Sphingolipids play a prominent role in cell signaling,
acting as both first and second messengers in a variety
of signaling and regulatory pathways [37]. Of all the
sphingolipids, ceramide and sphingosine, together with
their phosphorylated counterparts, have received the
most attention with regard to bioactivity. Ceramide has
been the benchmark, known for over 15 years to be
involved in apoptosis [38] and cell senescence [39], and
is now known to mediate many cell-stress responses,
making it difficult to find a cellular process that does
not involve ceramide, at least to some extent [11,36]. By
modulation of signaling pathways, including pleiotropic
effects on protein kinases, sphingosine has a role in
inducing cell cycle arrest and apoptosis, regulating the
actin cytoskeleton and endocytosis [40].
Sphingosine 1-phosphate is often referred to as the cer-
amide antagonist, as it is known for its cell proliferating
ability by regulating cell growth, survival and prolifera-
tion, as well as cell migration and inflammation [41]. Cer-
amide 1-phosphate has a role in inflammation and
vesicular trafficking [42], glucosylceramide in drug resis-
tance [43] and more recently a role for dihydroceramide
in cell regulation has been reported [44]. It is inevitable
that as the field of lipid metabolism continues to mature,
further sphingolipids and functions will be identified with
‘bioactive’ status. Although some mechanisms of sphin-
golipid action are known, (for example the pro-apoptotic
function of ceramide involves binding to protein kinase
Cζ [45]), efforts to determine how bioactive sphingolipids
transmit their respective signals will intensify.
Sphingolipids in Membranes
Sphingolipids are also important constituents of mem-
branes, and together with cholesterol and the
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yotic membranes. On the surface of mammalian cells
sphingolipids form patterns that are characteristic of the
cell type, and alter in response to cell growth, differen-
tiation, oncogenesis and external stimuli [46]. The lipid
composition also gives rise to the different phases in the
membrane, and thus begins the notion of the lipid raft
hypothesis. Sphingomyelin associates with cholesterol in
sphingolipid-/cholesterol-enriched domains, forming
microdomains termed lipid rafts [47,48]. The fatty acid
side chains of the phospholipids present in lipid rafts
tend to be more highly saturated than those in the sur-
rounding membrane. This facilitates tight packing with
the saturated acyl chains of the sphingolipids and, due
to the presence of cholesterol, a liquid ordered microdo-
main is formed that exhibits less fluidity than the sur-
rounding membrane. Lipid rafts can be isolated by their
resistance to solubilisation in non-ionic detergents and
buoyancy in sucrose, and we have used this approach to
characterise the lipid composition of rafts from cultured
cells [49]. Figure 4 shows an example of the distribution
of sphingolipids in cultured skin fibroblasts demonstrat-
ing that they predominate in the lipid raft domains
rather than the soluble membrane domains. Cholesterol
is believed to act as a spacer between the hydrocarbon
chains of the sphingolipids holding the rafts together
and, because it has a higher affinity to raft sphingolipids
than to unsaturated phospholipids, it partitions between
the raft and the rest of the membrane [50]. Although as
much as half of the plasma membrane may be
composed of rafts, it must be noted that many aspects
of raft structure remain controversial, primarily because
of the technical difficulties involved in their isolation
and characterisation [51].
The importance of sphingolipids in cellular events has
been underscored by the role of lipid rafts in intracellu-
lar signaling and vesicular trafficking [52]. Lipid rafts
facilitate interactions among the lipid and protein com-
ponents of signaling pathways, thereby regulating these
processes. Rafts have been implicated in promoting clus-
tering of receptors, which has been suggested to assist in
the organisation of signaling molecules. It is the unique
lipid composition of rafts that is believed to allow them
to carry out their signaling role. What happens to sig-
naling when the lipid composition of lipid rafts is
altered is one of the most intriguing questions in lipid
membrane biochemistry [53].
A seminal finding of lipid raft signaling was the obser-
vation that lipid rafts are crucial for the phosphoinosi-
tide-3 kinase (PI(3)K)/Akt signaling pathway [54], which
is essential for cell physiology. Upon growth factor sti-
mulation, PI(3)K catalyses the conversion of phosphati-
dylinositol (4,5)-bisphosphate to the second messenger
phosphatidylinositol (3,4.5)-triphosphate, that recruits
Akt from the cytosol to the plasma membrane. Here,
Akt goes through two phosphorylation events, one at a
threonine residue at the T-loop of Akt [55] and another
at a serine residue located at the C-terminal region of
the molecule [56], catalsyed by phosphoinositide-depen-
dent kinase 1 and 2, respectively, to activate Akt. Both
the phosphoinositide-dependent kinases and Akt are
located in lipid rafts and disturbing raft lipid composi-
tion alters cell survival and metabolism via the PI(3)K/
Akt signaling pathway [57,58].
Inborn Errors of Sphingolipid Metabolism
The importance of efficient sphingolipid degradation is
illustrated by the existence of inherited lysosomal glyco-
sidase and activator protein deficiencies that lead to a
group of lysosomal storage disorders known as the
sphingolipidoses [5]. The sphingolipidoses consist of at
least nine disorders, each resulting in the accumulation
of sphingolipids within the lysosomes of affected cells
(Table 1). The primary substrate that accumulates in the
lysosome, the substrate for the enzyme deficiency, leads
to a range of pathology that can involve the liver, spleen,
kidney, bone and central nervous system. Although the
primary enzymatic defects and the resulting clinical
pathologies have been well characterised for these disor-
ders, there is little known about the biochemical pro-
cesses leading to clinical pathology.
A fundamental question is how the lysosome accumu-
lates sphingolipids that can differ in as little as two hexose
attachments, can display such a disparate phenotype. For
Figure 4 Sphingolipid composition of lipid rafts and soluble
domains in cultured skin fibroblasts. Lipid rafts were isolated
from cultured skin fibroblasts (6 mg of total cell protein) and the
lipids present in each of the 12 fractions were extracted and
analysed by mass spectrometry as described previously [50].
Individual species of ceramide (Cer, closed squares),
glucosylceramide (GC, open diamonds), lactosylceramide (LC, closed
triangles) and trihexosylceramide (THC, crosses) were summed and
shown. Results are expressed as pmol lipid per mg of total protein.
Lipid rafts are localised to fractions 3 and 4.
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tion of ceramide trihexoside manifests as acroparesthesias,
angiokeratoma and occlusive vascular disease of the kid-
ney, heart or brain, compared with Gaucher disease where
accumulation of a monohexosylceramide leads to massive
hepatomegaly and splenomegaly. Such diverse and exten-
sive array of clinical manifestations suggests that many
secondary biochemical pathways involving, but not limited
to, sphingolipids must also be affected [59]. Beside the
accumulation of the primary sphingolipid substrate in the
sphingolipidoses, secondary sphingolipid alterations have
also been reported [8,60,61]. Perhaps this is not surprising
given the homeostatic response that would come into play
in attempt to restore the sphingolipid balance when the
degradation of one is impaired. It has been hypothesised
that an accumulation of lipids in lipid rafts in late endo-
somes/lysosomes has a role in the pathogenesis of the
sphingolipidoses [62]. This is evidenced in Niemann-Pick
C disease where cholesterol/sphingolipid accumulation
causes an overcrowding of rafts in the endocytic network
to form multilamellar bodies [63]. Additionally, alterations
in lipid raft composition occur in Gaucher disease [49].
Gaucher Disease
Gaucher disease is often considered the prototype for the
sphingolipidoses; not only is it the most prevalent lysoso-
mal storage disorder [64] it was also the first to be
described [65]. As such it has served as a model for the
treatment of other lysosomal storage disorders and
inborn errors of metabolism [66,67]. Gaucher disease is
inherited in an autosomal recessive manner and results
from the deficiency of acid b-glucosidase, the enzyme
responsible for the lysosomal hydrolysis of the sphingoli-
pid, glucosylceramide, to glucose and ceramide.
Insufficient acid b-glucosidase activity from more than
300 mutations in its gene has been shown to affect its
catalytic function, intracellular stability and/or trafficking
[68,69]. This enzyme dysfunction leads to the lysosomal
accumulation of glucosylceramide, which is also a meta-
bolic intermediate derived from the cellular turnover of
membrane gangliosides and globosides. The major site of
glucosylceramide storage is the cells of the mononuclear
phagocyte system, especially those in the liver, spleen,
lung and bone marrow. The accumulation of excess glu-
cosylceramide in macrophages is the main manifestation
in visceral organs, leading to hepatosplenomegaly, anae-
mia and thrombocytopaenia and bone involvement. Less
common is lung involvement, as well as many other
rather inconsistent manifestations [7]. Although the
pathology of Gaucher disease primarily results from the
storage of sphingolipids in tissues throughout the mono-
nuclear phagocyte system with subsequent macrophage
activation and tissue inflammation, the mechanisms
behind disease remain ill-defined [70].
The disease has been broadly categorised into three
clinical subtypes based on the presence and the rate of
rapidly advancing central nervous system pathology:
type 1 is the non-neuronopathic form exhibiting only
the visceral manifestations, and types 2 and 3 are the
acute and sub-acute neuronopathic variants, respec-
tively. Type 2 is generally seen in infancy with a rapid
neurodegenerative course and death usually within the
second year of life. Type 3 generally progresses with a
more chronic course, a later onset and a slower neuro-
degenerative path than type 2. Type 1 is more common,
with an estimated incidence of about 1 in 855 live-births
in the Ashkenazi Jewish population [7] and age of onset
highly variable. As with all of the sphingolipidoses, a
Table 1 The sphingolipidoses
disease clinical phenotype OMIM
number
enzyme deficiency primary stored sphingolipids
GM1-gangliosidosis types I/II/III 230500 b-galactosidase GM1 and GA1 ganglioside
GM2-gangliosidosis type A/B 272750 GM2-activator deficiency GM2 ganglioside
GM2-gangliosidosis type I (B
variant)
Tay-Sachs disease 272800 b-hexosaminidase A GM2 ganglioside
GM2-gangliosidosis type II (O
variant)




acid b-glucosidase or SAPC or
LIMP-2
glucosylceramide
Fabry disease 301500 a-galactosidase A ceramide trihexoside
metachromatic leukodystrophy 250100
249900
arylsulphatase A or SAPB sulphated galactosylceramide
globoid cell leukodystrophy Krabbe disease 245200 b-galactocerebrosidase galactosylceramide
Niemann-Pick type A/B Niemann-Pick
disease
257200 acid sphingomyelinase sphingomyelin
Farber lipogranulomatosis Farber disaese 301500 acid ceramidase ceramide
OMIM, Online Mendelian Inheritance in Man.
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genotype/phenotype correlations [71]. The advent of
enzyme replacement therapy has revolutionised the out-
look for individuals with type 1 Gaucher disease [67].
This therapy is very effective in reducing organ size and
correcting haematological abnormalities, however its
effect on skeletal and other complications of disease is
not so straightforward [72].
Sphingolipid Related Cellular Pathobiology
Although the characteristic sphingolipid laden macro-
phages are the hallmark of Gaucher disease, resulting in
macrophage activation and tissue inflammation, it is
clear that other homeostatic alterations underlie disease
symptomatology. With respect to sphingolipids, the pri-
mary storage of glucoslyceramide leads to secondary
alterations of sphingolipids that have been reported to
affect gangliosides in various tissues [73] and sphingo-
myelin in cell models of Gaucher disease [74]. We have
also shown secondary increases in ceramide, di- and tri-
hexosylceramides in a macrophage model of the disor-
der [8] and in fibroblasts from Gaucher patients [9].
Moreover, this secondary sphingolipid accumulation, as
well as glucosylceramide, was shown to extend beyond
the lysosome implying interference with biochemical
pathways at extralysosomal sites. It has also been pro-
posed that the secondary accumulation of other sphin-
golipids such as ceramide, sphingosine and sphingosine
1-phosphate act as signaling intermediaries to produce
an activation of macrophages, with the subsequent
release of pro-inflammatory cytokines [75].
The skeletal complications of Gaucher disease likely
relate to humoral factors produced by lipid laden
macrophages that ultimately alter bone remodelling
[76]. The observation of the critical role of circulating
sphingosine 1-phosphate in bone homeostasis suggests
involvement of this sphingolipid in Gaucher disease
[77]. In fact reduced sphingosine 1-phosphate levels
have been observed in mesenchymal stromal cells with
chemically induced inhibition of b-glucosidase to mimic
the Gaucher disease phenotype [78]. Additionally in this
model, and in mesenchymal stromal cells from a type 1
G a u c h e rp a t i e n tan u m b e ro f inflammatory mediators
were found to be upregulated. As sphingolipids are
involved in inflammation and apoptosis, they may have
a direct activating or enhancing effect on macrophage
function, which has been earlier postulated to be
mediated through calcium channel dysfunction [79].
Glucosylceramide and its catabolism to ceramide is, at
least in part, believed to have an immunomodulatory
effect by enhancing dendritic cells as well as natural
killer and regulatory T cells [80]. Although many of
these processes underlie these secondary disturbances,
much still remains to be learned to delineate the
metabolic pathways involved and the “triggers” for these
biochemical processes.
Recently the catabolic processes that occur in the lyso-
some were demonstrated to be directly involved in lipid
metabolism [81]. The key finding was that the process
of autophagy regulates lipid metabolism, by mobilising
intracellular lipid stores as an additional source of
energy. This indicates that lysosomes do not fuse
directly with cholesterol and triglyceride contained in
stored lipid droplets but rather fuse with lipid droplet
containing phagosomes. Although the exact mechanisms
of degradation of lipid droplets through autophagy
remain to be elucidated, it provides evidence for a role
for autophagy and lysosomal degradation in lipid meta-
bolism [82].
The effect of Sphingolipids on Insulin Sensitivity
Insulin resistance is defined as the reduced ability of a
cell to respond to physiological concentrations of insu-
lin. In normal physiological conditions following insulin
stimulation, insulin binds to the insulin receptor and
induces autophosphorylation via the receptor’s intrinsic
tyrosine kinase. The activated receptor phosphorylates a
family of insulin receptor substrate proteins which initi-
ates at least two signaling cascades. Firstly, Akt together
with protein kinase C, promotes translocation of the
glucose transporter (GLUT-4) to the plasma membrane
enabling the uptake of glucose, and secondly, the mito-
gen activated protein kinase cascade is initiated. Inter-
estingly, this latter cascade is not involved in either
insulin stimulated glucose transport or glycogen meta-
bolism [83]. The PI(3)K/Akt signaling pathway however,
is central to proper insulin signaling [84].
As discussed above, lipid rafts are required for effec-
tive PI(3)K/Akt signaling. Evidence suggests that as
there is a requirement for the spatiotemporal organiza-
tion of signaling components in plasma membrane
domains for effective insulin signaling [85]. Coupled
with the finding of the insulin receptor in lipid rafts
[86], the nature of the sphingolipids in these domains
may be one of the determining factors in the function-
ing of these signaling components and thereby insulin
signaling. A number of studies would support this and
imply that one of the many causes of insulin resistance
is related to altered sphingolipid metabolism. Firstly,
ceramide is known to inhibit insulin signaling via the
Akt signaling pathway, effectively blocking Akt activa-
tion. The mechanism prevents the translocation of Akt
to the plasma membrane and activation of the phos-
phoinositide-dependent kinase 2, which impairs Akt
activation by removing the activating phosphates [87].
Increased concentrations of ceramide have been
reported in skeletal muscle biopsies from obese humans
with insulin resistance [88], but further studies have
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that ceramide failed to increase in both insulin resistant
and type 2 diabetic patients compared to individuals
with a normal insulin response. Additionally, work
reported by Holland et al. [90] suggest that the types of
oils (lard oil high in saturated fatty acids, versus soy
bean oil, primarily unsaturated fatty acids) used in these
experiments may explain some of the disparity, as unsa-
turated fat has been shown to cause insulin resistance
independently of ceramide. Ceramide debate is likely to
continue until a consensus on its contribution to insulin
resistance can be achieved [91].
GM3 is another sphingolipid believed to interfere with
insulin signaling. Experiments in vivo using GM3
synthase knockout mice showed enhanced tyrosine
phosphorylation of the skeletal muscle insulin receptor
when compared with wild-type mice [92]. The addition
of GM3 to cultured 3T3-adipocytes was shown to sup-
press insulin stimulated tyrosine phosphorylation of the
insulin receptor and its downstream substrate, resulting
in impaired glucose uptake [93]. A proposed mechanism
f o rt h i si st h a tG M3 displaces the insulin receptor in
lipid rafts, impairing insulin receptor interaction and
effectively decreasing insulin receptor dependent signal-
ing [94]. In the lipid rafts the amount of GM3 doubled
whereas it remained unchanged in untreated 3T3-
adipocytes. Nonetheless the integrity of the insulin
receptor in rafts may be maintained via interaction with
lipid raft proteins such as caveolin. The potential role of
other sphingolipids in insulin resistance is somewhat
restricted. Sphingosine has received some attention, as
has glucosylceramide, although mechanisms of action
are purely speculative at this stage [95]. Further research
to link these mechanisms to impaired lipid raft function
due to interactions between sphingolipids present in the
rafts and the insulin receptor, as well as Akt and other
potential signalling pathways is needed.
Insulin Resistance and Gaucher Disease
The connection of sphingolipids to insulin resistance
has emanated from experimental findings outlined
above, demonstrating that sphingolipid metabolism
influences insulin sensitivity. It follows that Gaucher dis-
ease, a genetic disorder of sphingolipid metabolism, is a
useful human model to investigate the potential role of
sphingolipids in insulin resistance. To this end, impaired
insulin mediated glucose uptake has been demonstrated
in patients with Gaucher disease compared with unaf-
fected controls [96]. Although the number of Gaucher
patients investigated was only six making it difficult to
determine how widespread insulin resistance might be
in the Gaucher population. A subsequent study that
included larger numbers of Gaucher patients, some of
whom were receiving enzyme replacement, showed that
t h e r ew a sn oi n c r e a s ei nt h ep r e v a l e n c eo ft y p eI Id i a -
betes in Gaucher patients [97]. Interestingly, this study
found that the number of these Gaucher patients that
were overweight was less than in the general population,
and further findings of Ucar et al. [98] reported that
insulin resistance in Gaucher disease was not related to
overweight.
Energy balance is altered in mice models of lysosomal
storage disorders. Both a deficiency in adipose storage
and lower leptin levels were demonstrated in five differ-
ent lysosomal storage disorders, highlighting the involve-
ment of lipid metabolism [99]. This is in support of
earlier findings reporting increased energy expenditure
in Gaucher patients [100,101]. Clearly metabolic
abnormalities are apparent in Gaucher disease but the
administration of replacement enzyme to reduce gluco-
sylceramide levels in patients seems to bring about its
own metabolic consequences such as peripheral insulin
resistance [97]. It is not clear whether this is due to
reductions in glucosylceramide levels per se or second-
ary sphingolipid alterations, such as transient increases
in ceramide as the excess glucosylceramide passes
through the catabolic pathways. Recently it has been
suggested that individuals with Gaucher disease have a
selective advantage against some systemic disorders due
to the immunomodulatory effects of glucosylceramide
promoting dendritic cells, natural killer and regulatory T
cells [81]. This must be related at least in part to
restricted catabolism of glucosylceramide to ceramide.
Aside from the primary storage material, glucosylcera-
mide, a number of other lipids are also altered in
Gaucher disease. For example, we have observed eleva-
tions in GM3 in Gaucher disease [102], and elevations in
GM3 have been posited as playing a role in the insulin
resistance apparent in Gaucher disease [103]. Insulin
resistance has been referred to as a lipid raft disorder,
primarily on the basis of accumulation of GM3 which
results in a loss of the insulin receptor from lipid rafts
[104,105]. Lipid rafts have also been shown to be
affected in Gaucher disease [50]. The altered lipid raft
composition is likely to affect Akt signaling, (as dis-
cussed above), and preliminary data we have generated
using a Gaucher cell model suggest a role for the PI(3)/
Akt signaling pathway in Gaucher disease (unpublished).
Figure 5 shows that Akt phosphorylation is impaired in
a Gaucher cell model generated by chemical inhibition
of enzyme activity [50]. Thus, there is a clear link impli-
cating altered lipid raft composition and impaired Akt
signaling in both Gaucher disease and insulin resistance.
Probably the most direct pathogenic feature connect-
ing Gaucher disease with insulin resistance is macro-
phage activation leading to inflammation [71,106]. In
mice, insulin resistance caused by diet-induced obesity
produced a switch in macrophage polarisation from M2
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anti-inflammatory properties are considered M2,
whereas M1 refer to classically activated macrophages
which secrete pro-inflammatory cytokines such as IL-6
and TNFa, both of which are elevated in Gaucher dis-
ease and insulin resistance. This begs the question
whether M1 macrophages share similarities in Gaucher
disease and insulin resistance. The emerging scene
depicts macrophages subjected to an excessive lipid
load, which, in turn determines their function, and has a
substantial impact on cell, organ and tissue homeostasis.
The picture in Gaucher disease is one of enlarged liver
and spleen and insulin resistance reveals macrophage
infiltration of adipose tissue and muscle. The term lipo-
toxicity has been used to describe the continued accu-
mulation of lipids, and lipotoxicity in macrophages may
be at the cross-roads of Gaucher disease and insulin
resistance.
Reducing sphingolipid synthesis by inhibiting glucosyl-
ceramide synthase has been a therapeutic strategy for
Gaucher disease, but also corrects insulin resistance in
cultured adipocytes from obese individuals and in obese
rodents [108,109]. In doing so inflammation was also
shown to be mitigated as evidenced by reduced macro-
phage numbers and macrophage chemo attractants.
Inflammation is also a key pathogenic feature in Gau-
cher disease highlighting common elements between the
two conditions. Continuing to explore the interconnec-
tions between Gaucher disease and insulin resistance in
the future is likely to identify shared pathogenic aspects
which may present some novel opportunities for
treatment.
Concluding Remarks
In closing, the link between lysosomal storage disorders
and insulin resistance as membrane related disorders has
been known for more than 20 years, but the mechanisms
are yet to be clarified. Evidence exists that these mechan-
isms at least in some part, involve sphingolipids through
both their bioactive and structural (membrane) properties,
and thus converge on the lipid raft hypothesis. On reflec-
tion, much has been learnt about the role that sphingoli-
pids play in the biochemistry of disease, but we are a long
way from knowing the exact permutations and combina-
tions of sphingolipids involved. The manipulation of
sphingolipid metabolism using drugs and siRNA to speci-
fically alter the cell’s sphingolipid composition will be an
important experimental avenue to pursue. To this end
Gaucher disease will be a useful human model to study
the relationship between sphingolipid metabolism and
insulin resistance. One of the questions that remain unan-
swered is whether blocking the catabolism of ceramide or
other sphingolipids has any impact on insulin sensitivity?
Technology is advancing rapidly and tools such as mass
spectrometry now enable a detailed analysis of sphingoli-
pids in complex biological samples [110]. Unfortunately
we are still faced with the limitation of only being able to
take a snapshot of a cell at one particular point in time
which makes it difficult to put the pieces of the jigsaw
together to unravel what is going on biochemically in “real
time”. Thus, we are left with the paradoxical aim of inte-
grating both the biology and function of sphingolipids in a
dynamic system, yet at a stage where only static measure-
ments can be made. No doubt animal models will be used
to simulate the framework of interconnected events in the
immediate term, until this shortcoming can be overcome.
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